European Society of Cardiology Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Cypher DES: Johnson & Johnson/Cordis' Cypherdrug-eluting stent is significantly safer than bare-metal stents in complex cases where stents overlap, according to a meta-analysis of four Cypher trials presented by Martin Rothman, MD, London NHS Trust Hospital, at the European Society of Cardiology conference in Stockholm, Sept. 6. The analysis shows that overlapping Cypher stents are associated with a significantly lower rate of major adverse events than overlapping bare-metal stents - 7.4% versus 31.5% - and a lower rate of Q-wave myocardial infarction - 1.5% versus 4.6%. About 25% of all stent procedures require overlapping stents, according to Rothman. Studies included in the meta-analysis are SIRIUS, E-SIRIUS, DIRECT and SVELTE (1"The Gray Sheet" May 31, 2004, p. 13)...
You may also be interested in...
New labeling for Medtronic CRT
Revised labeling cleared by FDA for Medtronic's cardiac resynchronization therapy devices without defibrillation will reflect the technology's reduced risk of mortality and hospitalization. The labeling expansion is based upon results from the 813-patient CARE-HF trial of the firm's InSync and InSync III CRT-P devices, presented in 2005 (1"The Gray Sheet" Sept. 12, 2005, p. 13). The data, showing a 36%-40% reduction in all-cause mortality, provides validation that CRT devices "should be routinely used in patients with moderate to severe heart failure," William Abraham, MD, Ohio State University, says...
New labeling for Medtronic CRT
Revised labeling cleared by FDA for Medtronic's cardiac resynchronization therapy devices without defibrillation will reflect the technology's reduced risk of mortality and hospitalization. The labeling expansion is based upon results from the 813-patient CARE-HF trial of the firm's InSync and InSync III CRT-P devices, presented in 2005 (1"The Gray Sheet" Sept. 12, 2005, p. 13). The data, showing a 36%-40% reduction in all-cause mortality, provides validation that CRT devices "should be routinely used in patients with moderate to severe heart failure," William Abraham, MD, Ohio State University, says...
CRT-P Versus CRT-D: A Match-Up Likely Never To Be Seen – NEJM Editoral
Cardiac resynchronization with cardioverter defibrillation devices (CRT-D) will continue to be used more often than CRT-alone, even though the latter option may actually be better for some heart failure patients, according to John Jarcho, MD, Brigham & Women's Hospital, Boston